factor vii


Summary: Heat- and storage-stable plasma protein that is activated by tissue thromboplastin to form factor VIIa in the extrinsic pathway of blood coagulation. The activated form then catalyzes the activation of factor X to factor Xa.

Top Publications

  1. Berry S, Woodward R, Yeoh C, Miller G, Sanders T. Effect of interesterification of palmitic acid-rich triacylglycerol on postprandial lipid and factor VII response. Lipids. 2007;42:315-23 pubmed
    ..of this process on palmitic acid-rich fats are uncertain with regard to postprandial lipemia, insulin and factor VII activated (FVIIa) concentrations...
  2. Lu F, Hu Z, Sinard J, Garen A, Adelman R. Factor VII-verteporfin for targeted photodynamic therapy in a rat model of choroidal neovascularization. Invest Ophthalmol Vis Sci. 2009;50:3890-6 pubmed publisher
    To study the efficacy and safety of factor VII (fVII)-verteporfin for targeted photodynamic therapy (TPT) compared with nontargeted photodynamic therapy (PDT) in a rat model of choroidal neovascularization (CNV)...
  3. Tezel T, Bodek E, Sonmez K, Kaliappan S, Kaplan H, Hu Z, et al. Targeting tissue factor for immunotherapy of choroidal neovascularization by intravitreal delivery of factor VII-Fc chimeric antibody. Ocul Immunol Inflamm. 2007;15:3-10 pubmed
    ICON is a fusion protein composed of factor VII, the natural ligand for tissue factor, conjugated to the Fc domain of a human IgG1 immunoglobulin...
  4. Masroori N, Halabian R, Mohammadipour M, Roushandeh A, Rouhbakhsh M, Najafabadi A, et al. High-level expression of functional recombinant human coagulation factor VII in insect cells. Biotechnol Lett. 2010;32:803-9 pubmed publisher
    Recombinant coagulation factor VII (FVII) is used as a potential therapeutic intervention in hemophilia patients who produce antibodies against the coagulation factors...
  5. Hu Z, Li J. Natural killer cells are crucial for the efficacy of Icon (factor VII/human IgG1 Fc) immunotherapy in human tongue cancer. BMC Immunol. 2010;11:49 pubmed publisher
    ..We showed that Icon, as a chimeric factor VII and human IgG1 Fc immunoconjugate, could separately induce murine natural killer (NK) cells and activate ..
  6. Lwaleed B, Goyal A, Delves G, Gossai S, Greenfield R, Cooper A. Seminal factor VII and factor VIIa: supporting evidence for the presence of an active tissue factor-dependent coagulation pathway in human semen. Int J Androl. 2007;30:543-9 pubmed
    ..This finding reinforces the concept of an active clotting system in human semen, by establishing the missing link in the activation of a TF-dependent pathway. ..
  7. Johansson L, Karpf D, Hansen L, Pelzer H, Persson E. Activation peptides prolong the murine plasma half-life of human factor VII. Blood. 2011;117:3445-52 pubmed publisher
    ..Our data support that activation peptides function as plasma retention signals and constitute a new manner to extend the half-life of FVII(a). ..
  8. Sapsford W, Watts S, Cooper G, Kirkman E. Recombinant activated factor VII increases survival time in a model of incompressible arterial hemorrhage in the anesthetized pig. J Trauma. 2007;62:868-79 pubmed
    ..There are several anecdotal reports that recombinant activated factor VII (rFVIIa) may arrest uncontrolled bleeding after trauma...
  9. Fareed J, Bick R, Kessler C, Messmore H, Rao G, Sasahara A, et al. Potential thrombogenic complications with the use of recombinant activated factor VII in combat trauma. Clin Appl Thromb Hemost. 2007;13:121-3 pubmed

More Information


  1. Kogler V, Slobodnjak Z, Samarzija M, Macan J, Karadza V, Jakopovic M. Successful use of activated recombinant factor VII in life threatening bleeding after thoracic surgery. Swiss Med Wkly. 2007;137:407-10 pubmed
    ..whom life-threatening haemorrhage following lung resection was successfully managed using activated recombinant factor VII (NovoSeven)...
  2. Athanasiadis G, Esteban E, Gayà Vidal M, Dugoujon J, Moschonas N, Chaabani H, et al. Different evolutionary histories of the coagulation factor VII gene in human populations?. Ann Hum Genet. 2010;74:34-45 pubmed publisher
    ..Here, we investigate the evolutionary history of the Coagulation Factor VII gene (F7) by analysing five cardiovascular-risk-associated mutations from the F7 promoter and nine neutral ..
  3. Felfernig M, Huepfl M. Experience of recombinant activated factor VII (NovoSeven) in the operating theatre and intensive care unit for the management of intracranial bleeding in nonhaemophilic patients. Clin Neurol Neurosurg. 2008;110:227-32 pubmed
    ..Our aim was to explore the use of recombinant activated factor VII (rFVIIa NovoSeven Novo Nordisk, A/S, Bagsvaerd, Denmark) for the management of ICH in the operating theater and ..
  4. Zheng X, Kudaravalli R, Russell T, DiMichele D, Gibb C, Russell J, et al. Mutation in the factor VII hepatocyte nuclear factor 4?-binding site contributes to factor VII deficiency. Blood Coagul Fibrinolysis. 2011;22:624-7 pubmed publisher
    Severe coagulant factor VII (FVII) deficiency in postpubertal dizygotic twin males results from two point mutations in the FVII gene, a promoter region T?C transition at -60 and a His-to-Arg substitution at amino acid 348; both mutations ..
  5. May H, Hu Y, Zhang Y, Wang H, Fang J, Guo T, et al. [Expression of fusion protein encoding EGFP-EGF1 of rat coagulation factor VII and its binding function]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2008;16:181-4 pubmed
    This study was aimed at clarification of the function of EGF(1) segment in rat coagulation factor VII with tissue factor (TF) by means of the expression of the fusion protein of EGFP-EGF(1)...
  6. Hu Z, Rao B, Chen S, Duanmu J. Targeting tissue factor on tumour cells and angiogenic vascular endothelial cells by factor VII-targeted verteporfin photodynamic therapy for breast cancer in vitro and in vivo in mice. BMC Cancer. 2010;10:235 pubmed publisher
    The objective of this study was to develop a ligand-targeted photodynamic therapy (tPDT) by conjugating factor VII (fVII) protein with photosensitiser verteporfin in order to overcome the poor selectivity and enhance the effect of non-..
  7. Eroglu A, Ozturk A, Akar N. Association between the -402GA, -401GT, and -323ins10-bp polymorphisms of factor VII gene and breast cancer. Breast Cancer. 2011;18:282-5 pubmed publisher
    ..To test whether factor VII (FVII) can be a candidate factor for breast cancer, we have evaluated the distribution of FVII gene ..
  8. Tanaka R, Nakashima D, Suzuki A, Miyawaki Y, Fujimori Y, Yamada T, et al. Impaired secretion of carboxyl-terminal truncated factor VII due to an F7 nonsense mutation associated with FVII deficiency. Thromb Res. 2010;125:262-6 pubmed publisher
    b>Factor VII (FVII) is a vitamin K-dependent glycoprotein secreted into the blood circulation from hepatic cells. We investigated the molecular basis of the congenital FVII deficiency found in a Japanese patient...
  9. Fujimaki T, Kato K, Yoshida T, Oguri M, Watanabe S, Metoki N, et al. Association of genetic variants with myocardial infarction in Japanese individuals with chronic kidney disease. Thromb Haemost. 2009;101:963-8 pubmed
    ..Determination of genotype for the 11496G-->A (Arg353Gln) polymorphism of F7 may prove informative for assessment of the genetic risk for MI in individuals with CKD. ..
  10. Karatela R, Sainani G. Interrelationship between coagulation factor VII and obesity in diabetes mellitus (type 2). Diabetes Res Clin Pract. 2009;84:e41-4 pubmed publisher
    ..We found FVII hypercoagulant activity levels in DM not associated with obesity, leptin levels or insulin resistance. It was found independently associated with hypertriglyceridemia. ..
  11. Chen Y, Qiao J, Tan W, Lu Y, Qin S, Zhang J, et al. Characterization of porcine factor VII, X and comparison with human factor VII, X. Blood Cells Mol Dis. 2009;43:111-8 pubmed publisher
    b>Factor VII (FVII) and factor X (FX) are two predominant molecules of coagulation cascade. Whether porcine FVII and FX could efficiently work in human circulation is important for successful pig to human liver transplantation...
  12. Lapecorella M, Mariani G. Factor VII deficiency: defining the clinical picture and optimizing therapeutic options. Haemophilia. 2008;14:1170-5 pubmed publisher
    b>Factor VII (FVII) deficiency is the most frequent among rare congenital bleeding disorders, accounting for one symptomatic individual per 500,000 population, apparently without any racial/ethnic predilection...
  13. Wang J, Tan W, Chen Y, Lu X, Lu Y, Qin S, et al. Full-length cDNA cloning and protein three-dimensional structure modeling of factor VII of rhesus monkey, Macaca mulatta. Blood Cells Mol Dis. 2008;40:237-43 pubmed
    ..This study of rhesus monkey FVII might be helpful for understanding the function compatibility of human and rhesus monkey FVII, which is beneficial for the study of xenotransplantation. ..
  14. Pabinger I, Brenner B, Kalina U, Knaub S, Nagy A, Ostermann H. Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial. J Thromb Haemost. 2008;6:622-31 pubmed publisher
    ..PCC treatment serves as an effective rapid hemorrhage control resource in the emergency anticoagulant reversal setting. More widespread availability of PCC is warranted to ensure its benefits in appropriate patients. ..
  15. Wajih N, Owen J, Wallin R. Enhanced functional recombinant factor VII production by HEK 293 cells stably transfected with VKORC1 where the gamma-carboxylase inhibitor calumenin is stably suppressed by shRNA transfection. Thromb Res. 2008;122:405-10 pubmed publisher
    ..In this work we have engineered recombinant factor VII producing HEK 293 cells to stably overexpress VKORC1, the reduced vitamin K gamma-carboxylase cofactor and in ..
  16. Erem C, Kocak M, Hacihasanoglu A, Yilmaz M, Saglam F, Ersoz H. Blood coagulation, fibrinolysis and lipid profile in patients with primary hyperparathyroidism: increased plasma factor VII and X activities and D-Dimer levels. Exp Clin Endocrinol Diabetes. 2008;116:619-24 pubmed publisher
    ..This condition may contribute to the excess mortality rate due to CVD in patients with PHPT. ..
  17. Green D, Foiles N, Chan C, Kang J, Schreiner P, Liu K. An association between clotting factor VII and carotid intima-media thickness: the CARDIA study. Stroke. 2010;41:1417-22 pubmed publisher
    To investigate associations of procoagulants (factor VII [FVII], FVIII, von Willebrand factor) with subclinical atherosclerosis, we examined participants in the Coronary Artery Risk Development in Young Adults (CARDIA) study...
  18. Girolami A, Berti de Marinis G, Bonamigo E, Allemand E. Worldwide diffusion of FVII Arg304Gln coagulation defect (FVII Padua). Eur J Haematol. 2011;86:135-9 pubmed publisher
    ..The defect is characterized by low FVII activity when rabbit brain thromboplastins are used in the assay system. On the contrary, FVII levels are normal when ox-brain thromboplastins are used. FVII antigen is always normal. ..
  19. Knudsen T, Kjelgaard Hansen M, Tranholm M, Wiinberg B, Clausen J, Hansen J, et al. Canine specific ELISA for coagulation factor VII. Vet J. 2011;190:352-8 pubmed publisher
    Canine coagulation factor VII (FVII) deficiency can be hereditary or acquired and may cause life threatening bleeding episodes if untreated...
  20. Maguire J, Thakkinstian A, Sturm J, Levi C, Lincz L, Parsons M, et al. Polymorphisms in platelet glycoprotein 1balpha and factor VII and risk of ischemic stroke: a meta-analysis. Stroke. 2008;39:1710-6 pubmed publisher
    ..of this meta-analysis is to test the hypothesis that genetic variation in the platelet glycoprotein 1balpha and Factor VII genes influence the occurrence of ischemic stroke...
  21. Ponschab M, Landoni G, Biondi Zoccai G, Bignami E, Frati E, Nicolotti D, et al. Recombinant activated factor VII increases stroke in cardiac surgery: a meta-analysis. J Cardiothorac Vasc Anesth. 2011;25:804-10 pubmed publisher
    Recombinant activated factor VII (rFVIIa) is used in various surgical procedures to reduce the incidence of major blood loss and the need for re-exploration. Few clinical trials have investigated rFVIIa in cardiac surgery...
  22. Yokota N, Koizume S, Miyagi E, Hirahara F, Nakamura Y, Kikuchi K, et al. Self-production of tissue factor-coagulation factor VII complex by ovarian cancer cells. Br J Cancer. 2009;101:2023-9 pubmed publisher
    ..TF binds to coagulation factor VII (fVII), changing it to its active form, fVIIa. This leads to activation of the extrinsic coagulation cascade...
  23. Karatela R, Sainani G. Interrelationships of Factor VII activity and plasma leptin with insulin resistance in coronary heart disease. Atherosclerosis. 2010;209:235-40 pubmed publisher
    ..Raised FVII and leptin levels in CHD patients were independently associated with insulin resistance, this was not observed among the non-CHD subjects. ..
  24. Mota L, Shetty S, Idicula Thomas S, Ghosh K. Phenotypic and genotypic characterization of Factor VII deficiency patients from Western India. Clin Chim Acta. 2009;409:106-11 pubmed publisher
    Congenital factor VII (FVII) deficiency is a rare coagulation deficiency caused due to defects in the FVII gene...
  25. Mariani G, Bernardi F. Factor VII Deficiency. Semin Thromb Hemost. 2009;35:400-6 pubmed publisher
    The complex formed between the procoagulant serine protease activated factor VII (FVII) and the membrane protein tissue factor, exposed on the vascular lumen upon injury, triggers the initiation of blood clotting...
  26. Funami J, Hayashi T, Nomura H, Ding Q, Ishitsuka Watanabe A, Matsui Hirai H, et al. Clinical factors such as B-type natriuretic peptide link to factor VII, endothelial NO synthase and estrogen receptor alpha polymorphism in elderly women. Life Sci. 2009;85:316-21 pubmed publisher
    ..acts in or is related to either blood coagulation (factor V Leiden, prothrombin G20210A, factor XIII Val34Leu, factor VII Arg353Gln, MTHFR C677T, beta-fibrinogen G-455A, PAI-1 4G/5G), metabolic syndrome-related pathways (PPARalpha ..
  27. Freeman D, Tham K, Brown E, Rumley A, Lowe G, Greer I. Fetal corticotrophin-releasing hormone mRNA, but not phosphatidylserine-exposing microparticles, in maternal plasma are associated with factor VII activity in pre-eclampsia. J Thromb Haemost. 2008;6:421-7 pubmed publisher
    ..001) in pre-eclampsia. Placental debris, assessed by fetal CRH mRNA levels in maternal blood, is related to coagulation potential, i.e. FVII activity, but not to markers of coagulation or endothelial activation in pre-eclampsia. ..
  28. Taylor K, Lange L, Zabaneh D, Lange E, Keating B, Tang W, et al. A gene-centric association scan for Coagulation Factor VII levels in European and African Americans: the Candidate Gene Association Resource (CARe) Consortium. Hum Mol Genet. 2011;20:3525-34 pubmed publisher
    Polymorphisms in several distinct genomic regions, including the F7 gene, were recently associated with factor VII (FVII) levels in European Americans (EAs). The genetic determinants of FVII in African Americans (AAs) are unknown...
  29. Bertolucci C, Cavallari N, Colognesi I, Aguzzi J, Chen Z, Caruso P, et al. Evidence for an overlapping role of CLOCK and NPAS2 transcription factors in liver circadian oscillators. Mol Cell Biol. 2008;28:3070-5 pubmed publisher
    ..b>Factor VII (FVII), the protease triggering blood coagulation, represents a valuable model to address this issue in liver ..
  30. Fenaille F, Groseil C, Ramon C, Riandé S, Siret L, Chtourou S, et al. Mass spectrometric characterization of N- and O-glycans of plasma-derived coagulation factor VII. Glycoconj J. 2008;25:827-42 pubmed publisher
    b>Factor VII (FVII) is a vitamin K-dependent glycoprotein which, in its activated form (FVIIa), participates in the coagulation process by activating factor X and factor IX. FVII is secreted as single peptide chain of 406 residues...
  31. Girolami A, Berti de Marinis G, Bonamigo E, Vettore S. Similarities and discrepancies in homozygous factor VII defects due to mutations in the region of residues Met298 to Cys310 (exon 8) in the catalytic domain of factor VII. Lab Hematol. 2011;17:17-21 pubmed publisher
    Patients with the Arg304Gln mutation in factor VII Padua (FVII Padua) show discrepant activity levels that depend on the thromboplastin used in the assay system...
  32. Weiskopf R. Recombinant-activated coagulation factor VIIa (NovoSeven): current development. Vox Sang. 2007;92:281-8 pubmed
    Recombinant activated coagulation factor VII (rFVIIa) was developed initially for treatment of patients with hemophilia and neutralizing antibodies ("inhibitors") to coagulation factors VIII or IX...
  33. Hoffman M, Colina C, McDonald A, Arepally G, Pedersen L, Monroe D. Tissue factor around dermal vessels has bound factor VII in the absence of injury. J Thromb Haemost. 2007;5:1403-8 pubmed
    ..The presence of endogenously bound FVIIa prevents the subsequent binding of the monospecific antibody or exogenous FVIIai to perivascular TF. ..
  34. Girolami A, Bertozzi I, De Marinis G, Bonamigo E, Fabris F. Activated FVII levels in factor VII Padua (Arg304Gln) coagulation disorder and in true factor VII deficiency: a study in homozygotes and heterozygotes. Hematology. 2011;16:308-12 pubmed publisher
    ..The abnormal factor VII present in these forms may, in fact show, different levels of activity, according to the thromboplastin used in ..
  35. Branchini A, Rizzotto L, Mariani G, Napolitano M, Lapecorella M, Giansily Blaizot M, et al. Natural and engineered carboxy-terminal variants: decreased secretion and gain-of-function result in asymptomatic coagulation factor VII deficiency. Haematologica. 2012;97:705-9 pubmed publisher
    ..R462X mutation affecting the carboxy-terminus of coagulation factor VII (FVII, 466 aminoacids). FVII levels of 3-5% and 2.7 ± 0...
  36. Jayandharan G, Viswabandya A, Nair S, Chandy M, Srivastava A. Molecular basis of hereditary factor VII deficiency in India: five novel mutations including a double missense mutation (Ala191Glu; Trp364Cys) in 11 unrelated patients. Haematologica. 2007;92:1002-3 pubmed
    ..These mutations were considered to be causative of disease because of their nature, evolutionary conservation and molecular modeling. This is the first report of mutations in patients with FVII deficiency from southern India. ..
  37. Franchini M, Manzato F, Salvagno G, Lippi G. Potential role of recombinant activated factor VII for the treatment of severe bleeding associated with disseminated intravascular coagulation: a systematic review. Blood Coagul Fibrinolysis. 2007;18:589-93 pubmed
    Recombinant activated factor VII (rFVIIa) is a novel hemostatic agent, originally developed for the treatment of hemorrhage in hemophiliacs with inhibitors, which has been successfully used recently in an increasing number of ..
  38. Davidson S, Turner N, Tillyer L. Anticoagulation of a patient with hypertrophic cardiomyopathy and factor VII deficiency. Blood Coagul Fibrinolysis. 2010;21:707-8 pubmed publisher
    ..His baseline prothrombin time was prolonged and further investigation showed the patient to have a mild factor VII deficiency...
  39. Ken Dror G, Drenos F, Humphries S, Talmud P, Hingorani A, Kivimaki M, et al. Haplotype and genotype effects of the F7 gene on circulating factor VII, coagulation activation markers and incident coronary heart disease in UK men. J Thromb Haemost. 2010;8:2394-403 pubmed publisher
    ..The haplotype associated with low FVIIc level, with particularly reduced functional activity, was consistently associated with increased risk for CHD, whereas the haplotype associated with high FVIIc level was not. ..
  40. Cocco E, Hu Z, Richter C, Bellone S, Casagrande F, Bellone M, et al. hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor for immunotherapy of uterine serous papillary carcinoma. Br J Cancer. 2010;103:812-9 pubmed publisher
    ..molecule (hI-con1) is an antibody-like molecule targeted against tissue factor (TF), composed of two human Factor VII (fVII) as the targeting domain, fused to human immunoglobulin (Ig) G1 Fc as an effector domain...
  41. Giansily Blaizot M, Thorel D, Khau Van Kien P, Behar C, Romey M, Mugneret F, et al. Characterisation of a large complex intragenic re-arrangement in the FVII gene (F7) avoiding misdiagnosis in inherited factor VII deficiency. Br J Haematol. 2007;138:359-65 pubmed
    Inherited factor VII (FVII) deficiency is a rare autosomal recessive bleeding disorder mostly caused by point mutations...
  42. Xu Z, Xu H, Ploplis V, Castellino F. Factor VII deficiency impairs cutaneous wound healing in mice. Mol Med. 2010;16:167-76 pubmed publisher
    ..The results from these studies demonstrate an in vivo mechanistic relationship between FVIIa, Egr-1 and the inflammatory response in keratinocyte function during the wound healing process. ..
  43. Smith N, Chen M, Dehghan A, Strachan D, Basu S, Soranzo N, et al. Novel associations of multiple genetic loci with plasma levels of factor VII, factor VIII, and von Willebrand factor: The CHARGE (Cohorts for Heart and Aging Research in Genome Epidemiology) Consortium. Circulation. 2010;121:1382-92 pubmed publisher
    ..Nine of the 10 new findings were replicated. New genetic associations were discovered outside previously known biological pathways and may point to novel prevention and treatment targets of hemostasis disorders. ..
  44. Bysted B, Scharling B, Møller T, Hansen B. A randomized, double-blind trial demonstrating bioequivalence of the current recombinant activated factor VII formulation and a new robust 25 degrees C stable formulation. Haemophilia. 2007;13:527-32 pubmed
    ..VII25's 'user-friendly' formulation removes the inconvenience of storing/transporting at 2-8 degrees C, and as the drug substance is the same, the activity and safety established for rFVIIa is maintained. ..
  45. Huang H, Jia S, Chen S, Sha Y, Ma A, Ma X, et al. [The coagulation factor VII gene polymorphisms in patients with myocardial infarction in Ningxia Hui and Han populations]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2009;26:653-8 pubmed publisher
    To investigate the characteristics for activated coagulation factor VII(F VIIa) and the R353Q, -323 0/10 bp, HVR4 polymorphisms in the gene in patients with coronary heart disease (CHD) and myocardial infarction from Ningxia Hui and Han ..
  46. Pinotti M, Balestra D, Rizzotto L, Maestri I, Pagani F, Bernardi F. Rescue of coagulation factor VII function by the U1+5A snRNA. Blood. 2009;113:6461-4 pubmed publisher
    ..minigenes have demonstrated that an engineered small nuclear RNA-U1 (U1+5a) partially rescued coagulation factor VII (FVII) mRNA processing impaired by the 9726+5G>A mutation...
  47. Kanse S, Parahuleva M, Muhl L, Kemkes Matthes B, Sedding D, Preissner K. Factor VII-activating protease (FSAP): vascular functions and role in atherosclerosis. Thromb Haemost. 2008;99:286-9 pubmed publisher
    ..role in the regulation of coagulation and fibrinolysis is postulated, based on its property to activate factor VII (FVII) as well as pro-urokinase (uPA)...
  48. Bowman R, Joosen A, Welch A, Luben R, Khaw K, Wareham N, et al. Factor VII, blood lipids and fat intake: gene-nutrient interaction and risk of coronary heart disease with the factor VII R353Q polymorphism. Eur J Clin Nutr. 2009;63:771-7 pubmed publisher
    The relation between dietary fat, blood lipids, plasma factor VII coagulant activity (FVIIc) and risk of coronary heart disease (CHD) according to the R353Q polymorphism in the factor VII gene was assessed...
  49. Roldan V, Marin F, Gonzalez Conejero R, García Honrubia A, Martí S, Alfaro A, et al. Factor VII -323 decanucleotide D/I polymorphism in atrial fibrillation: implications for the prothrombotic state and stroke risk. Ann Med. 2008;40:553-9 pubmed publisher
    ..We hypothesized that a functional haemostatic polymorphism, that is, the factor VII -323 Del/Ins polymorphism, would influence the prothrombotic state associated with AF, as well as stroke risk...
  50. Koizume S, Yokota N, Miyagi E, Hirahara F, Nakamura Y, Sakuma Y, et al. Hepatocyte nuclear factor-4-independent synthesis of coagulation factor VII in breast cancer cells and its inhibition by targeting selective histone acetyltransferases. Mol Cancer Res. 2009;7:1928-36 pubmed publisher
    Tissue factor/coagulation factor VII (fVII) complex formation on the surface of cancer cells plays important roles in cancer biology, such as cell migration and invasion, angiogenesis, and antiapoptotic effects...
  51. Cocco E, Varughese J, Buza N, Bellone S, Lin K, Bellone M, et al. Tissue factor expression in ovarian cancer: implications for immunotherapy with hI-con1, a factor VII-IgGF(c) chimeric protein targeting tissue factor. Clin Exp Metastasis. 2011;28:689-700 pubmed publisher
  52. Herrmann F, Wulff K, Auerswald G, Schulman S, Astermark J, Batorova A, et al. Factor VII deficiency: clinical manifestation of 717 subjects from Europe and Latin America with mutations in the factor 7 gene. Haemophilia. 2009;15:267-80 pubmed publisher
    ..The severe haemorrhages - intracranial and gastrointestinal - were not reported in heterozygous subjects. The clinical variability and the regional differences in the mutation pattern are discussed regarding care and treatment. ..
  53. Suzuki A, Miyawaki Y, Okuyama E, Murata M, Ando Y, Kato I, et al. Ribavirin-induced intracellular GTP depletion activates transcription elongation in coagulation factor VII gene expression. Biochem J. 2013;449:231-9 pubmed publisher
    Coagulation FVII (Factor VII) is a vitamin K-dependent glycoprotein synthesized in hepatocytes...